Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.

CONTEXT Lipodystrophies are extreme forms of metabolic syndrome. Metreleptin was approved in the United States for generalized lipodystrophy (GLD) but not partial lipodystrophy (PLD). OBJECTIVE The objective of the study was to test metreleptin's efficacy in PLD vs GLD and find predictors for treatment response. DESIGN This was a prospective, single-arm, open-label study since 2000 with continuous enrollment. Current analysis included metreleptin treatment for 6 months or longer as of January 2014. SETTING The study was conducted at the National Institutes of Health (Bethesda, Maryland). PARTICIPANTS Patients clinically diagnosed with lipodystrophy, leptin less than 8 ng/mL (males) or less than 12 (females), age older than 6 months, and one or more metabolic abnormalities (diabetes, insulin resistance, or hypertriglyceridemia) participated in the study. INTERVENTION The interventions included sc metreleptin injections (0.06-0.24 mg/kg · d). MAIN OUTCOMES AND MEASURES Changes in glycated hemoglobin A1c (HbA1c) and triglycerides after 6 and 12 months of metreleptin were measured. RESULTS Baseline metabolic parameters were similar in 55 GLD [HbA1c 8.4% ± 2.3%; triglycerides, geometric mean (25th, 75th percentile), 467 mg/dL (200, 847)] and 31 PLD patients [HbA1c 8.1% ± 2.2%, triglycerides 483 mg/dL (232, 856)] despite different body fat and endogenous leptin. At 12 months, metreleptin decreased HbA1c (to 6.4% ± 1.5%, GLD, P < .001; 7.3% ± 1.6%, PLD, P = .004) and triglycerides [to 180 mg/dL (106, 312), GLD, P < .001; 326 mg/dL (175, 478), PLD, P = .02]. HbA1c and triglyceride changes over time significantly differed between GLD and PLD. In subgroup analyses, metreleptin improved HbA1c and triglycerides in all GLD subgroups except those with baseline triglycerides less than 300 mg/dL and all PLD subgroups except baseline triglycerides less than 500 mg/dL, HbA1c less than 8%, or endogenous leptin greater than 4 ng/mL. CONCLUSIONS In addition to its proven efficacy in GLD, metreleptin is effective in selected PLD patients with severe metabolic derangements or low leptin.

[1]  K. Rother,et al.  Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. , 2014, The Journal of clinical endocrinology and metabolism.

[2]  R. Shamburek,et al.  Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. , 2014, The Journal of clinical endocrinology and metabolism.

[3]  D. Kleiner,et al.  The liver diseases of lipodystrophy: the long-term effect of leptin treatment. , 2013, Journal of hepatology.

[4]  C. Mantzoros,et al.  Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. , 2013, Endocrine reviews.

[5]  C. Quittner,et al.  Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. , 2012, The Journal of clinical endocrinology and metabolism.

[6]  P. Gorden,et al.  Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. , 2012, The Journal of clinical endocrinology and metabolism.

[7]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[8]  J. Chan,et al.  Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[9]  A. Garg.  Lipodystrophies: Genetic and Acquired Body Fat Disorders , 2011 .

[10]  C. Mantzoros,et al.  Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance , 2011, Diabetes.

[11]  Vandana Sachdev,et al.  Cardiomyopathy in Congenital and Acquired Generalized Lipodystrophy: A Clinical Assessment , 2010, Medicine.

[12]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[13]  V. Basevi.  Standards of medical care in diabetes--2007. , 2009, Diabetes care.

[14]  K. Clément,et al.  Leptin therapy for partial lipodystrophy linked to a PPAR‐γ mutation , 2008, Clinical endocrinology.

[15]  G. Sebag,et al.  Metabolic Correction Induced by Leptin Replacement Treatment in Young Children With Berardinelli-Seip Congenital Lipoatrophy , 2007, Pediatrics.

[16]  P. Gorden,et al.  Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. , 2007, Metabolism: clinical and experimental.

[17]  T. Kusakabe,et al.  Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[19]  P. Gorden,et al.  Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. , 2005, Diabetes.

[20]  T. Shawker,et al.  Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth , 2005, Clinical Endocrinology.

[21]  P. Gorden,et al.  The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. , 2005, Metabolism: clinical and experimental.

[22]  J. Yanovski,et al.  Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. , 2004, The Journal of clinical endocrinology and metabolism.

[23]  S. O’Rahilly,et al.  Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. , 2004, The Journal of clinical endocrinology and metabolism.

[24]  Y. Matsuzawa,et al.  Serum adiponectin and leptin levels in patients with lipodystrophies. , 2004, The Journal of clinical endocrinology and metabolism.

[25]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[26]  R. Hammer,et al.  Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy , 1999, Nature.

[27]  S. Klein,et al.  Radioimmunoassay of leptin in human plasma. , 1996, Clinical chemistry.

[28]  R. Considine,et al.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.

[29]  P. Gorden,et al.  Efficacy of leptin therapy in the different forms of human lipodystrophy , 2009, Diabetologia.

[30]  A. Garg,et al.  Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. , 2003, Diabetes care.

[31]  T. Cole.  The LMS method for constructing normalized growth standards. , 1990, European journal of clinical nutrition.